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In Reply: Drs Grey and Cundy indicate their dissatisfaction with the intervention thresholds for osteoporosis treatment recommended by the National Osteoporosis Foundation (ie, 3% absolute risk of hip fracture or 20% risk of major osteoporotic fracture during a 10-year period). 1 We understand that intervention thresholds will vary by practitioner, patient, and country, and we agree that a robust discussion about appropriate thresholds is important. We do believe, however, that cost-effectiveness analyses can be helpful in setting public health policy.
Furthermore, using the same assumptions of Grey and Cundy, the number needed to treat to prevent a major osteoporotic fracture for patients at the lowest-risk intervention threshold is only 25 during a 5-year period, and will decrease further as absolute fracture risk increases. Nevertheless, we are happy that Grey and Cundy accept our premise that absolute fracture risk, which takes into account individualized risk factors, be used to determine treatment instead of relying solely on bone density T-score.
The survey cited by Grey and Cundy reported that patients are willing to accept an extraordinarily high absolute risk of hip fracture (50% risk during a 10-year period) before they would consider osteoporosis treatment. 2 We believe that the large discrepancy between public and physician assessment of the risk-to-benefit ratio for osteoporosis treatment is due to the medical community's failure to educate the public properly about the serious consequences of osteoporotic fractures as well as misperceptions of the potential risks.
We advocate arming patients with information about the rates of permanent disability and excess mortality associated with osteoporotic fractures, 3 as well as providing a fair assessment of the ability of osteoporosis treatments to effectively prevent fractures at relatively low risk. 4 Perhaps then the discrepancies in perception about osteoporosis treatment can be resolved and adherence to treatment can be improved.
Dr Gourlay and colleagues provide follow-up information from their longitudinal study of bone density from the Study of Osteoporotic Fractures cohort. 5 Their additional calculations more accurately define the decline in T-scores over time for our example patient. Because we did not have access to the primary data, we had assumed a constant rate of bone loss over the period (as stated in our Viewpoint). Nevertheless, the fundamental point remains that incorporating clinical risk factors into an intervention decision would result in more frequent bone density screening intervals to identify women who are at risk of fracture prior to reaching an osteoporotic T-score of −2.5.
We agree with Gourlay and colleagues that ideally a randomized controlled trial should be performed to validate the efficacy of osteoporosis therapies in patients identified using absolute fracture risk thresholds. Unfortunately, such a trial is unlikely to occur due to the considerable size and expense that would be required. Given that T-score cutoffs for the diagnosis of osteoporosis are arbitrary and insensitive, 6 we instead advocate a more individualized and we believe rational approach for risk stratification, incorporating age and other clinical risk factors in addition to bone density. 
RESEARCH LETTER

Off-Label Use of Bone Morphogenetic Proteins in Pediatric Spinal Arthrodesis
To the Editor: Arthrodesis of the spine is frequently performed in children. Although nonunion occurs frequently in adults, children rarely experience nonunion. 1 We are aware of no evidence to support the need for augmentation beyond instrumentation and autograft bone grafting in pediatric spinal arthrodesis.
Bone morphogenetic proteins (BMPs) are approved for limited use in adults when healing may be suboptimal.
2,3 In addition to concerns about possible carcinogenesis, complications include wound dehiscence, spinal stenosis, and respiratory complications. 4 The US Food and Drug Administration has not approved the use of BMPs in children.
We determined the prevalence of BMP use, associated complications, costs, and potential predictors of use in pediatric spinal arthrodesis in the United States.
Methods. The Kids´Inpatient Database, Healthcare Cost and Utilization Project, a sample of 4121 US hospitals containing 10% of uncomplicated births and 80% of complicated pediatric admissions representing approximately 30% of total pediatric admissions, is weighted to allow calculation of national estimates. 5 We included children aged 18 years or younger who had undergone primary or revision spine arthrodesis in 2009 using International Classification of Diseases, Ninth Revision, Clinical Modification diagnoses and procedure codes as previously described by Cahill et al. 6 SAS version 9.2 (SAS Institute Inc) was used, accounting for the complex survey design to calculate appropriate standard errors and P values and to provide nationally representative weighted estimates of prevalence of BMP use, inhospital complications, length of stay, and in-hospital costs. Costs were estimated from supplied charges data using hospital-specific cost-to-charge ratios from the Healthcare Cost and Utilization Project.
Multivariable logistic regression was used to determine the independent association of diagnoses, comorbidities, demographic factors, and insurance status with BMP use (TABLE) . Complications assessed included medical, neurological, wound healing, infectious, and those related to breath- LETTERS ing and dysphagia. 6 The institutional review board at the Hospital for Sick Children approved the study and waived participant consent.
Results. In 2009, 8289 pediatric spinal arthrodeses were in the Kids´Inpatient Database. Nationally, BMP was estimated to be used in 9.2% (95% CI, 7.3%-11.0%; unweighted n=771) of cases. The estimated prevalence of inhospital complications in those who received BMP was 3.0% (95% CI, 2.0%-4.1%; unweighted n = 24) and in those who did not receive BMP was 3.6% (95% CI, 3.0%-4.2%; unweighted n=271) (Rao-Scott 2 = 0.74; P= .39 for comparison across BMP groups).
The median total in-hospital adjusted costs for patients receiving BMP was $47 136 (interquartile range [IQR], $30 692-$73 848) and in those not receiving BMP was $43 126 (IQR, $31 246-$59 849) (PϽ.001). Adjusted analysis of log-transformed costs showed that surgeries using BMP were 19% (95% CI, 10%-28%) more costly than those not using BMP. Median length of stay for patients receiving BMP was 4.6 days (IQR, 3.2-6.9 days) and for those not receiving BMP was 4.6 days (IQR, 3.5-6.1 days) (P =.70).
Use of BMP was associated with older age, lumbosacral arthrodeses, fewer vertebrae fused, spondylolisthesis, neurofibromatosis, revision fusions, and surgeries performed in the Midwest. Use of BMP was less frequent in idiopathic scoliosis, specialized pediatric hospitals, and in patients with Medicare or Medicaid health coverage (Table) .
Comment. Given the lack of indication for augmentation of pediatric spinal arthrodesis, the use of BMP in 9.2% of patients is surprising. Although no difference in the rate of in-hospital complications was demonstrated, most complications previously reported with BMP are late complications and would not be expected to occur during hospitalization. While it is possible that some unmeasured factors account for the increase in costs associated with BMP use, our adjusted analysis showed that surgeries using BMP were 19% more costly than those that did not involve BMP use. Although BMP was used for diagnoses considered higher risk for nonunion, such as neurofibromatosis, BMP was still used frequently in idiopathic scoliosis and for other lowrisk diagnoses. This study was limited by lack of longitudinal data in the Kids´Inpatient Database, as well as lack of details on dosage and type of BMP. Use of BMP should not be routine in pediatric spine arthrodesis until it has been shown to be safe and beneficial.
